(Q35580997)

9 August 2017

1 reference

title

Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer (English)

1 reference

9 August 2017

Bisphosphonates to Prevent Skeletal Complications in Men With Metastatic Prostate Cancer (English)

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

31 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

31 March 2024

author name string

Matthew R. Smith

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14610411

31 March 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

http://api.elsevier.com/content/article/PII:S0022534701682570?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

http://api.elsevier.com/content/article/PII:S0022534701682570?httpAccept=text/plain

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

http://www.jurology.com/doi/pdf/10.1097/01.ju.0000095102.34708.bc

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

31 March 2024

1 reference

9 August 2017

volume

170

1 reference

9 August 2017

issue

6 Pt 2

1 reference

9 August 2017

page(s)

S55-7; discussion S57-8

1 reference

Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer

9 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Growth regulatory properties of endothelins

31 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Morphometric evidence for bone resorption and replacement in prostate cancer

31 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Osteoblast function and osteomalacia in metastatic prostate cancer

31 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption

31 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

31 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

31 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Overview of bisphosphonates

31 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

31 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption

31 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

31 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

31 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

31 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.

31 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer

31 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

31 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Treatment of painful prostatic bone metastases with oral etidronate disodium

31 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

31 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

31 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

31 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000095102.34708.BC

31 March 2024

Identifiers

1 reference

9 August 2017

1 reference